Medicare 2027 rule changes: What older adults and caregivers need to know about drug rebates and costs

Federal changes to how Medicare plans report and treat drug rebates and discounts can sound technical, but they can affect what beneficiaries pay, how prescriptions are covered, and how caregivers should plan. This guide translates the Medicare Program contract-year 2027 provisions on rebates, discounts and regulatory scoring into clear, practical advice for beneficiaries, family caregivers and care managers.

Quick summary: What the 2027 rule focuses on

The contract-year 2027 Medicare rule clarifies reporting and accounting standards for rebates, discounts and other price concessions between drug manufacturers, pharmacy benefit managers (PBMs), and plans. In short, it asks plans to report prices "net of" (after) discounts and rebates. The rule also notes that CMS did not score some provisions in the regulatory impact analysis because industry participants are already complying with similar practices.

Why this matters

• Price reporting affects how CMS evaluates plans, and can change public price transparency tools.
• How rebates flow — to plans or directly reducing patient costs at checkout — affects out-of-pocket (OOP) spending for beneficiaries.
• Changes in reporting and scoring can influence plan premiums, formularies, and negotiations with drug makers.

How rebates currently affect beneficiaries

Historically, many manufacturer rebates are negotiated between drug companies and plan sponsors (or PBMs) after a drug is dispensed. Those rebates typically lower a plan's net cost but often do not reduce the amount a beneficiary pays at the pharmacy counter. That means a patient paying coinsurance (a percentage of the drug price) might pay more when list prices are high even if the plan later receives a rebate.

Medicare Part D mechanics (brief)

1. Deductible phase: Beneficiary pays until the deductible is met (if the plan has one).
2. Initial coverage: Beneficiary and plan share costs.
3. Coverage gap ("donut hole"): Manufacturer discounts for brand drugs have historically counted toward true out-of-pocket costs (TrOOP) for entering catastrophic coverage, though rules vary by year.
4. Catastrophic coverage: After high OOP spending, Medicare covers most drug costs.

Rebate policy can affect where a beneficiary falls in these phases and how quickly they reach catastrophic coverage.

What the 2027 rule could mean for your out-of-pocket costs

Because the 2027 rule centers on reporting prices net of rebates and discounts, beneficiaries may see several downstream changes — but not all are guaranteed:

• More transparent pricing: If plans report net prices more consistently, price-comparison tools (including Medicare Plan Finder) may show costs that better reflect what plans really pay. That can help when comparing plans during open enrollment.
• Potential premium impacts: If rebates are more clearly recognized as reducing plan costs, plans could lower premiums or reallocate savings — but whether savings reach beneficiaries depends on plan design decisions and regulation.
• No automatic point-of-sale reductions: The 2027 reporting rules by themselves don't necessarily require that rebates be passed through to patients at checkout. Unless plans are required to apply rebates at point-of-sale, beneficiaries who face coinsurance based on list prices may not see immediate reductions.
• Formulary and access shifts: Better accounting of rebates can change plan negotiations with manufacturers and influence which drugs are placed on preferred formulary tiers. This can affect prior authorization, step therapy and whether a brand drug or generic is used.

Actionable steps beneficiaries and caregivers can take now

Even before rules fully shift market behavior, there are practical steps caregivers and beneficiaries should take to plan for potential changes in 2027.

1. Review your plan during open enrollment with an emphasis on drug costs

Use the Medicare Plan Finder and your plan’s formulary to compare total expected annual costs — premiums, deductibles, copays/coinsurance and estimated drug costs. Look beyond premiums: a low-premium plan can be expensive if it has high cost-sharing for the medicines you actually need.

2. Estimate true out-of-pocket spending with scenarios

Create a simple yearly estimate for the beneficiary’s medications. For each prescription, note:

• List price vs. plan tier copay/coinsurance
• Whether a generic is available
• Past prior authorization or step therapy hurdles

Then simulate: if rebates lowered net plan costs but were not applied at point-of-sale, would that change your OOP? If not, consider switching to plans that offer flat copays or lower coinsurance for your high-cost meds.

3. Ask pharmacies and plans specific questions

• Does my coinsurance apply to the drug’s list price or a net-of-rebate price?
• Do rebates apply at the point-of-sale or only after claims are processed?
• Are there preferred alternatives (a therapeutic alternative or generic) that lower my OOP?

4. Tap financial help resources

Programs such as Extra Help (Low-Income Subsidy), state pharmaceutical assistance programs, manufacturer patient-assistance programs, and local State Health Insurance Assistance Programs (SHIPs) can lower costs. If you expect changes in plan design for 2027, reach out early to understand eligibility and enrollment timelines.

5. Plan for formulary changes and prior authorization

Because rebate-driven negotiations can change which drugs a plan favors, keep copies of medical records, prior authorization letters and documentation showing medical necessity. If a drug is moved to a non-preferred tier or requires step therapy, prepare to appeal and request exceptions when clinically justified.

How caregivers can support medication access and cost management

• Maintain an organized medication list with doses, prescribing doctor, and reasons for each drug. This helps when calling plans, pharmacies, and clinicians.
• Track monthly out-of-pocket spending to anticipate entering coverage gap or catastrophic phases.
• Ask clinicians about therapeutic alternatives that are clinically appropriate and less costly.
• Coordinate with pharmacists to check for manufacturer coupons, coupons that may not apply to Medicare, or generic substitution options.

Common questions beneficiaries ask (FAQ)

Will Medicare make manufacturers apply rebates at point-of-sale?

Not necessarily. The 2027 rule focuses primarily on reporting and accounting for rebates (reporting prices net of discounts and rebates). Whether rebates reduce the price you pay at the pharmacy depends on separate policy actions. Keep watching CMS announcements and plan documents for any point-of-sale rebate rules.

If my plan receives large rebates, should I expect my premium to fall?

Possibly, but plans can use rebates in different ways — to lower premiums, reduce premiums for certain groups, fund additional benefits, or improve plan finances. Transparency and CMS oversight push toward greater public knowledge of rebate use, but the timing and amount of premium changes are determined by plan decisions and market competition.

Could rebates improve access to certain drugs?

Yes — stronger negotiations can lead plans to prefer certain drugs with favorable net prices, potentially improving access to those drugs at lower tiers. Conversely, drugs with weak rebate arrangements could be placed on higher-cost tiers or subject to utilization management tools, which might make access harder for some patients.

Policy context and what to watch next

Reporting rules that require net-of-rebate accounting aim to make plan costs and pricing more transparent, which can inform better regulation and consumer tools. Watch for:

• Further CMS guidance on point-of-sale rebate pass-throughs.
• Plan-level disclosures on how rebates are used (premiums vs. benefits).
• State-level pharmacy laws that interact with federal rules (for example, allowing certain price concessions to be passed to customers).

For broader context about how financial incentives and institutional behavior shape healthcare markets, see our article on how financial institutions impact healthcare innovation. Supply chain and access issues can also affect availability of medications — learn more in our piece on supply chain disruptions and healthcare.

Checklist: Preparing for Medicare 2027 changes

1. Make a medicines list and estimate annual OOP costs under current plan.
2. Compare plans during open enrollment, focusing on estimated drug costs and tiers.
3. Contact your plan and pharmacy to ask whether OOP is calculated on net or list prices.
4. Check eligibility for Extra Help and state pharmacy assistance programs.
5. Ask prescribers about clinically appropriate lower-cost options or prior-authorized exceptions.
6. Keep documentation to support appeals if coverage changes affect access.

Final takeaways

The Medicare 2027 rule refines how rebates and discounts are reported and accounted for, which should increase transparency — a useful step for consumers. However, transparency alone does not automatically reduce what a beneficiary pays at the pharmacy counter. Caregivers and beneficiaries should proactively review plans, estimate true drug costs for the coming year, and use available assistance programs. Staying informed and organized is the best way to limit surprise costs and maintain access to necessary prescriptions as rules and plan behaviors evolve.

If you need hands-on help, contact your local State Health Insurance Assistance Program (SHIP) or use Medicare.gov’s help resources and tools to compare plans and estimate drug costs.